多发性骨髓瘤患者接受BCMA靶向CAR T治疗后挽救治疗的干预与结局
该研究分析了两家学术机构79例BCMA靶向CAR T治疗后进展的多发性骨髓瘤患者的挽救治疗与结局,共使用237线挽救治疗,中位2线(范围1-10)。CAR T后复发日起中位总生存17.9个月(95%CI 14.0-不可估计),首次挽救方案总缓解率43.4%,中位无进展生存3.5个月(CI 2.5-4.6);35例(44.3%)接受T细胞衔接治疗,其中位随访21.3个月后总生存未达到。
要点
- BCMA靶向CAR T后复发患者中位总生存17.9个月(95%CI 14.0-不可估计)。
- 首次挽救方案总缓解率43.4%,中位无进展生存3.5个月(CI 2.5-4.6)。
- 35例(44.3%)接受T细胞衔接治疗,中位随访21.3个月后总生存未达到。
核心结论
- BCMA靶向CAR T后复发的多发性骨髓瘤患者预后有限,但可能接受多线挽救治疗。
- T细胞衔接治疗在该情形下似乎保持显著的临床活性。
研究设计与样本
- 分析两家学术机构79例BCMA靶向CAR T治疗后疾病进展的多发性骨髓瘤患者的挽救治疗与结局。
- 共使用237线CAR T后挽救治疗,患者接受中位2线(范围1-10)治疗。
主要发现
- CAR T治疗后复发日起中位总生存17.9个月(95%CI 14.0-不可估计)。
- 首次挽救方案总缓解率43.4%,中位无进展生存3.5个月(CI 2.5-4.6)。
- 35例(44.3%)接受T细胞衔接治疗(双特异性抗体或后续CAR T)作为挽救治疗。
- 接受后续T细胞衔接治疗的患者在中位随访21.3个月后总生存未达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration-approved BCMA-directed CAR T products. However, despite high initial response rates, most patients eventually relapse. The outcomes of patients with disease recurrence after BCMA-directed CAR T have not been comprehensively studied, and such an analysis would help define optimal treatment strategies. We analyzed the salvage treatments and outcomes of 79 patients with multiple myeloma from two academic institutions, who had progression of disease after treatment with BCMA-directed CAR T. A total of 237 post-CAR T salvage treatment lines were used, and patients received a median of 2 (range, 1-10) treatment lines. The median overall survival from the date of relapse post-CAR T therapy was 17.9 months (95% confidence interval [CI], 14.0 non-estimable). The overall response rate to the first salvage regimen was 43.4%, with a median progression-free survival of 3.5 months (CI, 2.5-4.6). Thirty-five patients (44.3%) received a T-cell-engaging therapy (bispecific antibody or subsequent CAR T) as salvage treatment. The overall survival in patients who received subsequent T-cell-engaging therapy was not reached after a median follow up of 21.3 months. Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy. T-cell-engaging therapies appear to maintain pronounced clinical activity in this setting.
引用
- Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023. PMID: 36327160. doi:10.1182/blood.2022017848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。